S. Brod

发表

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Michael Wall, J. Herbert, Jack H. Simon, 2002, Neurology.

Immune reconstitution therapy in NMOSD.

S. Brod, 2021, Multiple sclerosis and related disorders.

Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects

S. Brod, 2020, Multiple Sclerosis and Related Disorders.

Plegia to walking: AHSCBMT in severe NMOSD relapse

P. Hari, S. Brod, Nicola Carlisle, 2020, BMJ Neurology Open.

Interferon-beta sub 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

G. Marshall, J. Wolinsky, S. Sriram, 1996, Neurology.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

Myelinating Proteins in MS Are Linked to Volumetric Brain MRI Changes

J. Lincoln, F. Nelson, S. Brod, 2019, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis

H. Weiner, D. Hafler, S. Brod, 1992 .

Ingested (oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice.

S. Brod, Zachary M. Hood, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Ingested interferon-alpha prevents allograft islet transplant rejection.

S. Stepkowski, S. Brod, S. Katz, 2000, Transplantation.

Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice

S. Darcan, S. Brod, M. Malone, 1998, Diabetologia.

Effect of Ingested Interferon-α on β-Cell Function in Children With New-Onset Type 1 Diabetes

D. Harlan, K. Rother, Rebecca J. Brown, 2009, Diabetes Care.

Gut response. Therapy with ingested immunomodulatory proteins.

S. Brod, 1997, Archives of neurology.

Common T‐cell receptor Vβ usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis

H. Weiner, D. Hafler, K. Wucherpfennig, 1991, Annals of neurology.

Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment

L. Kramer, P. Narayana, J. Wolinsky, 2013, Multiple sclerosis.

Contrasted Enhanced Magnetic Resonance Venography with Gadofosveset Trisodium

L. Kramer, P. Narayana, J. Wolinsky, 2012 .

CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

G. Freeman, D. Hafler, M. Dorf, 1992, Journal of immunology.

The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

S. Brod, 2022, Autoimmunity reviews.

Combination therapy with glatiramer acetate (copolymer‐1) and a type I interferon (IFN‐α) does not improve experimental autoimmune encephalomyelitis

J. Wolinsky, S. Brod, J. W. Lindsey, 2000, Annals of neurology.

Ingested (oral) anti-IL-12/23 inhibits EAE

S. Brod, 2016, Journal of the Neurological Sciences.

Ingested (oral) tocilizumab inhibits EAE.

S. Brod, V. Bauer, 2014, Cytokine.

Ingested (oral) thyrotropin releasing factor (TRH) inhibits EAE.

S. Brod, V. Bauer, 2013, Cytokine.

Ingested (oral) neuropeptide Y inhibits EAE

S. Brod, V. Bauer, 2012, Journal of Neuroimmunology.

Ingested (oral) SST inhibits EAE

S. Brod, Zachary M. Hood, 2011, Autoimmunity.

Ingested (oral) ACTH inhibits EAE

S. Brod, Zachary M. Hood, 2011, Journal of Neuroimmunology.

Ingested (oral) SIRS peptide 1–21 inhibits acute EAE by inducing Th2-like cytokines

S. Brod, Zachary M. Hood, 2007, Journal of Neuroimmunology.

Frequency analysis of CD4+CD8+ T cells cloned with IL-4.

D. Hafler, S. Brod, D. Benjamin, 1990, Cellular immunology.

Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons

D. Burns, S. Brod, Staley A. Brod, 1994, Neurology.

Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes.

M. Atkinson, P. Brosnan, S. Brod, 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Ingested IFN- a Preserves Residual b Cell Function in Type 1 Diabetes

M. Atkinson, P. Brosnan, S. Brod, 2001 .

Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens.

H. Weiner, R. Sobel, S. Khoury, 1991, Annals of the New York Academy of Sciences.

Adoptive Transfer From Interferon-&agr;–Fed Mice Is Associated With Inhibition of Active Experimental Autoimmune Encephalomyelitis by Decreasing Recipient Tumor Necrosis Factor-&agr; Secretion

S. Brod, Mohammed Khan, E. Henninger, 2000, Journal of immunotherapy.

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the lewis rat and strain 13 guinea pig

H. Weiner, D. Hafler, R. Sobel, 1991, Annals of neurology.

Chronic Cerebrospinal Venous Insufficiency: Case–Control Neurosonography Results

L. Kramer, P. Narayana, J. Wolinsky, 2013, Annals of neurology.

Ingested (oral) rituximab inhibits EAE.

S. Brod, 2016, Cytokine.

Variable results after rituximab in neuromyelitis optica

J. Wolinsky, F. Nelson, S. Brod, 2012, Journal of the Neurological Sciences.

Immunoregulation in multiple sclerosis.

H. Weiner, D. Hafler, S. Brod, 1989, Research in immunology.

Sclerosis and Experimental Autoimmune EncephalomyelitisMultiple in the Central Nervous System in the Mouse Model of Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17

B. Dittel, S. Brod, Landon J. Dittel, 2022 .

Lack of antibodies to Borrelia burgdorferi in patients with amyotrophic lateral sclerosis.

A. Steere, T. Munsat, S. Brod, 1989, The New England journal of medicine.

Oral ACTH (H.P. Acthar(®)Gel) inhibits IL-1 and IL-17 secretion in humans.

S. Brod, V. Bauer, Zachary M. Hood, 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory disease.

D. Hafler, S. Brod, D. Benjamin, 1991, Journal of immunology.

Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons.

D. Burns, M. Scott, S. Brod, 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

A proposal: How to study pro-myelinating proteins in MS.

S. Brod, 2021, Autoimmunity reviews.

In MS: Immunosuppression is passé.

S. Brod, 2020, Multiple sclerosis and related disorders.

Ingested IFN-α has biological effects in humans with relapsing-remitting multiple sclerosis

G. Marshall, J. Wolinsky, R. Jin, 1997 .

Oral Administration of IFN-α is Superior to Subcutaneous Administration of IFN-α in the Suppression of Chronic Relapsing Experimental Autoimmune Encephalomyelitis

S. Brod, Mohammed Khan, 1996 .

Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2

S. Brod, 2010, Pharmaceuticals.

Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity

S. Brod, 2002, Experimental biology and medicine.

Ingested type I interferon: a potential treatment for autoimmunity.

S. Brod, 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Unregulated inflammation shortens human functional longevity

S. Brod, 2000, Inflammation Research.

Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system.

S. Brod, 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments

F. Nelson, S. Brod, J. W. Lindsey, 2019, Multiple sclerosis journal - experimental, translational and clinical.

Ingested interferon alpha induces Mx mRNA.

J. Wolinsky, R. Jin, S. Brod, 1999, Cytokine.

Idiopathic CSF pleocytosis in relapsing polychondritis

J. Booss, S. Brod, 1988, Neurology.

Antigen‐Driven Peripheral Immune Tolerance

H. Weiner, D. Hafler, R. Sobel, 1991 .

Ingested (oral) alpha-MSH inhibits acute EAE

S. Brod, Zachary M. Hood, 2008, Journal of Neuroimmunology.

T‐T cell interactions are mediated by adhesion molecules

D. Hafler, David A. Hafler, Staley A. Brod, 1990, European journal of immunology.

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease.

S. Brod, 2021, Journal of Alzheimer's disease : JAD.

Increased in Vitro Induced CD4+ and Cd8+ T Cell Ifn-GM and CD4+ T Cell Il-10 Production in Stable Relapsing Multiple Sclerosis

J. Wolinsky, S. Brod, M. Khan, 1997 .

Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis.

M. Scott, S. Brod, 1994, Autoimmunity.

Ingested Type I Interferon in Experimental Autoimmune Encephalomyelitis

S. Brod, 2005 .

Decreased CD3‐mediated interferon‐γ production in relapsing‐remitting multiple sclerosis

G. Marshall, J. Wolinsky, S. Sriram, 1995, Annals of neurology.

Hypothesis: Multiple Sclerosis is a Type I Interferon Deficiency Syndrome

S. Brod, 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis

M. Pappolla, R. Kerman, S. Brod, 1995, Journal of Neuroimmunology.

Predictors of success for drug discontinuation following neonatal seizures.

R. Ehrenkranz, L. Ment, S. Bridgers, 1988, Pediatric neurology.

LYMPHOKINE REGULATION OF CD 45 R EXPRESSION ON HUMAN T CELL CLONES

D. Hafler, C. Rudd, S. Brod, 2003 .

Lymphokine regulation of CD45R expression on human T cell clones

D. Hafler, C. Rudd, S. Brod, 1989, The Journal of experimental medicine.

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis.

G. Shipley, S. Brod, Zachary M. Hood, 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Ingested IFN-α

Jerry S. Wolinsky, P. Narayana, J. S. Wolinsky, 2001, Neurology.

Contrast enhanced MR venography with gadofosveset trisodium: Evaluation of the intracranial and extracranial venous system

K. Hasan, L. Kramer, P. Narayana, 2014, Journal of magnetic resonance imaging : JMRI.

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Arnold, J. Selhorst, R. Kinkel, 2006, Neurology.

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.

J. Wolinsky, S. Brod, M. Khan, 1997, The International journal of neuroscience.

Oral administration of type I interferon modulates the course of experimental allergic neuritis.

M. Pappolla, S. Brod, M. Khan, 1996, Autoimmunity.

Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.

G. Marshall, J. Wolinsky, R. Jin, 1997, Multiple sclerosis.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

J. Wolinsky, P. Narayana, C. Ahn, 2001, Neurology.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

M. Freedman, B. Hayward, B. Cohen, 2019, Journal of Neurology.

Bio-equivalence of IM and SQ H.P. Acthar Gel.

S. Brod, Miriam M. Morales, 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice.

S. Darcan, S. Brod, M. Malone, 1998, Diabetologia.

Eye movements, EEG, and fatal anoxic coma

R. Mattson, J. Ebersole, S. Brod, 1988 .

Treatment of autoimmune diseases by oral tolerance to autoantigens.

H. Weiner, R. Sobel, S. Khoury, 1995, Advances in Experimental Medicine and Biology.

Primary omphalomesenteric adrenocarcinoma with metastases to the brain.

S. Spencer, S. Brod, J. Kim, 1988, Surgical neurology.

Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis

B. Dittel, S. Brod, Landon J. Dittel, 2022, ImmunoHorizons.

Lymphokine Regulation of Cd45r Expression on Human T Cell Clones Materials and Methods Brief Definitive Report

S. Brod, M. Purvee, C. E. Rudd, 2022 .

Ingested ACTH blocks Th17 production by inhibiting GALT IL-6

B. Dittel, S. Brod, Landon J. Dittel, 2019, Journal of the Neurological Sciences.

Variable results after rituximab in neuromyelitis optica

J. Wolinsky, F. Nelson, S. Brod, 2012, Journal of the Neurological Sciences.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

J. Selhorst, C. Kollman, R. Kinkel, 2006, Neurology.

Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis

B. Dittel, S. Brod, Landon J. Dittel, 2023, Journal of the Neurological Sciences.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

C. Bever, L. Weiner, J. Wolinsky, 2000, Multiple Sclerosis.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

J S Wolinsky, J. Wolinsky, P. Narayana, 2001, Multiple sclerosis.

Ingested (oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice.

S. Brod, Zachary M. Hood, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Contrast enhanced MR venography with gadofosveset trisodium: Evaluation of the intracranial and extracranial venous system

K. Hasan, P. Narayana, J. Wolinsky, 2014, Journal of magnetic resonance imaging : JMRI.